Tech Company Financing Transactions
Angitia Biopharmaceuticals Funding Round
Angitia Biopharmaceuticals closed a $120 million Series C financing round on 12/11/2024. Investors included Bain Capital Life Sciences, 3H Health Investment and Elikon Venture.
Transaction Overview
Company Name
Announced On
12/11/2024
Transaction Type
Venture Equity
Amount
$120,000,000
Round
Series C
Investors
Proceeds Purpose
Proceeds from the Series C will support Angitia's robust pipeline of novel, differentiated treatments for serious musculoskeletal diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5850 Canoga Ave 400
Woodland Hills, CA 91367
USA
Woodland Hills, CA 91367
USA
Phone
Undisclosed
Website
Email Address
Overview
Our mission is to discover, develop, and commercialize breakthrough therapeutics that address large unmet medical needs of patients with serious musculoskeletal diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Hua Ke
Chief Financial Officer
Mike Arenberg
Chief Medical Officer
Willard Dere
Chief Operating Officer
Muyu Li
Chief Technical Officer
Lei Zheng
VP - Bus. Development
Tom Storey
VP - R & D
Xiaofeng Liu
Browse more venture capital transactions:
Prev: 12/11/2024: NeuBird venture capital transaction
Next: 12/11/2024: Wavegate venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs